การใช้ยาลีโวฟล็อคซาซินเพื่อลดความเสี่ยงของการเกิดไข้จากภาวะเม็ดเลือดขาวต่ำ ในผู้ป่วยมะเร็งเต้านมที่ได้รับการรักษาด้วยยาเคมีบำบัด

Abstract

The use of levofloxacin for reducing rate of chemotherapy-induced febrile neutropenia in breast cancer patients which remains controversial. Methods: We conducted a randomized double-blind placebo-controlled trial in patients who were receiving cyclic chemotherapy for breast cancer and at intermediate risk of febrile neutropenia. The 53 patients who on 216 chemotherapy cycle were randomly assigned to receive either 500 mg of levofloxacin placebo. Results: The 2.8 percent of patients in the levofloxacin group had febrile neutropenia less than 9.3 percent of patients in the placebo group significantly (p value = 0.045). The incidence of febrile neutropenia in the first cycle (16.1 percent) is more than in the later cycle (4.3 percent). Conclusions: The administration of levofloxacin reduces risk of chemotherapy-induced febrile neutropenia in breast cancer patients who have intermediate risk. Levofloxacin prophylaxis should be offered routinely to these group of patients and during in the first cycle of chemotherapy.